Search CORE

6 research outputs found

Direct acting anti-hepatitis C virus drugs: Clinical pharmacology and future direction

Author: DAKLINZA
DAKLINZA
EPCLUSA
EPCLUSA
HARVONI
HARVONI
OLYSIO
OLYSIO
SOVALDI
SOVALDI
VIEKIRA PAK
VIEKIRA PAK
ZEPATIER
ZEPATIER
Publication venue: 'Walter de Gruyter GmbH'
Publication date
Field of study

Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens

Author: Kowdley
Lalezari
Lawitz
Lawitz
Osinusi
Rodriguez-Torres
Sovaldi (sofosbuvir) tablets
Publication venue: 'Wiley'
Publication date
Field of study

Stability Indicating RP-HPLC Method for Estimation of Potential Impurities in Ledipasvir and Characterization of a New Degradation Impurity

Author: Au
ICH Guidelines
Kowdley
Lawitz
Liang Jake
Pan
Sharma
Sovaldi (sofosbuvir) tablets: US prescribing information
Publication venue: 'Oxford University Press (OUP)'
Publication date
Field of study

Successes and Challenges on the Road to Cure Hepatitis C

Author: AYM Howe
C Moreno
DB Smith
DR Nelson
H Kumada
Harvoni
JG McHutchison
K Mohd Hanafiah
L Rong
M Manns
MS Sulkowski
MS Sulkowski
O Falkowski
Olysio
R Lozano
Richard C. Condit
RT Chung
Sovaldi
Stacy M. Horner
Susanna Naggie
V Lo Re
V Mallet
Viekira Pak
Publication venue: 'Public Library of Science (PLoS)'
Publication date
Field of study

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial

Anti-Nuclear Cytoplasmic Antibody-Associated Vasculitis: A Probable Adverse Effect of Sofosbuvir Treatment in Chronic Hepatitis C Patients

core

core